The Patent Dance, Decoded: How Biosimilar Developers Win (or Lose) Before Litigation Starts
In the biosimilar world, the fight rarely begins in a courtroom. It begins in a spreadsheet.
Before a single complaint is filedor a single expert report is exch…

Drug patent cliffs are no longer a later problem. Theyre a data problemsolvable now.
If youre still treating patent expiration and litigation risk as something you react to, youre already behind.
In the pharma world, the calendar is unforgiving: exclus…

Patent thickets arent just a legal inconveniencetheyre a market design problem. And if youre a pharma executive, investor, or in-house counsel, the real question isnt Can we clear patents? Its: Can we build a repeatable strategy that clears them faster…

Blockbuster drugs dont just have patentsthey have recipes. And if youre trying to design around them, the real battleground is often not the active ingredient, but the formulation itself.
Thats the core idea behind formulation forensics: using public s…

Pharma boards dont get sued for patents. People do. Companies get sued for what those patents enableand for what they fail to protect.
Thats why the most important shift in IP leadership isnt legal strategy. Its governance.
In a world where patent liti…

Designing Around Formulation Patents: The Generic Developers Playbook (and Why Its Getting Harder)
In generic drug development, the real fight often isnt about whether you can make a moleculeits about how you can make it.
Formulation patentscovering ev…

Pharma forensics is having a momentand its not just for patent attorneys.
In an industry where timelines are everything, the real competitive advantage often isnt the molecule. Its the lifecycle strategy: how a company extends exclusivity, reshapes mar…

Designing Around the Moat: How Generic Developers Can Navigate Secondary Formulation Patents
In generic drug development, the first battle is obvious: challenge the primary patent. But the second battlethe one that quietly determines timelines, costs, …

Patent cliff or patent opportunity? Mapping blockbuster expirations for strategic supply-chain readiness
The market loves a clean narrative: patent cliff = chaos, price collapse, and operational whiplash.
But the reality for pharma supply chains is m…

AI is getting better at finding whats not there. Thats a big deal for pharma IP.
In patent litigation and prosecution, the hardest prior art isnt always the obvious stuff. Its the hidden stuffthe references buried in long chemical descriptions, the alm…